Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last --
Change Today 0.00 / 0.00%
Volume 0.0
8086 On Other Exchanges
8086 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

nipro corp (8086) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NIPRO CORP (8086)

Related News

No related news articles were found.

nipro corp (8086) Related Businessweek News

View More BusinessWeek News

nipro corp (8086) Details

Nipro Corporation, together with its subsidiaries, engages in the medical equipment, pharmaceuticals, and glass businesses in Japan, the United States, Europe, and rest of Asia. The company’s Medical-Related Business segment offers injection and infusion products, artificial organ products, functional products, dialysis products, and diabetic products, as well as renal, intervention and anesthesiology, cardiopulmonary, and pharmaceutical kit products. Its Pharmaceutical-Related Business segment provides injectable drugs, including injection kits, etc.; oral drugs, such as orally-disintegrating tablets, etc.; generic anti-cancer drugs and biosimilars; and drugs for external use. The company’s Glass-Related Business segment offers tube glass for pharmaceuticals, vials, and ampoules; and glass material products for thermos bottles and lighting. Nipro Corporation is also involved in the rental of real estate properties. The company was founded in 1954 and is headquartered in Osaka, Japan.

23,153 Employees
Last Reported Date: 06/26/15
Founded in 1954

nipro corp (8086) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

nipro corp (8086) Key Developments

Nipro Corporation Announces Consolidated Earnings Results for the First Three Months Ended June 30, 2015; Provides Guidance for the Six Months Ending September 30, 2015 and for the Year Ending March 31, 2015

Nipro Corporation announced consolidated earnings results for the first three months ended June 30, 2015. For the period, the company reported net sales of JPY 88,097 million compared to JPY 75,424,000 a year ago. Operating income of JPY 5,476 million compared to JPY 2,801 million a year ago. Ordinary income of JPY 5,852 million compared to JPY 2,146 million a year ago. Income before income taxes of JPY 6,061 million compared to JPY 3,458 million a year ago. Net income of JPY 3,990 million or JPY 23.03 earnings per share compared to JPY 1,306 million or 8.31 earnings per share a year ago. Net income attributable to owners of parent JPY 3,904 million compared to JPY 1,252 million a year ago. For the six months ending September 30, 2015, the company expects net sales of JPY 174,000 million, ordinary income of JPY 9,700 million, operating income of JPY 12,700 million, net income of JPY 3,950 million, and earnings per share of JPY 23.30. For the year ending March 31, 2016, the company expects net sales of JPY 362,000 million, operating income of JPY 27,500 million, ordinary income of JPY 22,500 million, net income of JPY 13,700 million, and earnings per share of JPY 80.80.

Nipro Corporation to Report Q1, 2016 Results on Aug 11, 2015

Nipro Corporation announced that they will report Q1, 2016 results on Aug 11, 2015

Nipro and Otsuka Sign Agreement to Provide TB Drug Delamanid in Indonesia

Nipro and Otsuka Pharmaceutical have entered into a collaboration with Japan International Cooperation Agency to support the Indonesian government's efforts to control its tuberculosis (TB) epidemic, according to Nikkei. Otsuka will provide TB drug delamanid, while Nipro aims to provide for free its app that informs patients when to take the treatment. Nipro also plans to sell TB detection kits as early as spring 2016.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8086:JP ¥1,254.00 JPY +21.00

8086 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dr Reddy's Laboratories Ltd 4,178 INR -54.80
Fuso Pharmaceutical Industries Ltd ¥272.00 JPY 0.00
JMS Co Ltd ¥280.00 JPY +1.00
Nikkiso Co Ltd ¥834.00 JPY +36.00
NxStage Medical Inc $15.56 USD +0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation 8086 Industry Range
Price/Earnings 13.2x
Price/Sales 0.6x
Price/Book 1.3x
Price/Cash Flow 14.3x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NIPRO CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at